D. E. Shaw & Co., Inc. Edgewise Therapeutics, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding EWTX
# of Institutions
191Shares Held
100MCall Options Held
2.17MPut Options Held
410K-
Orbimed Advisors LLC San Diego, CA15MShares$446 Million9.45% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.91MShares$264 Million3.32% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$178 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY5.84MShares$173 Million1.67% of portfolio
-
Novo Holdings Hellerup, G75.55MShares$165 Million10.36% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $1.87B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...